Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Interest & Investment Income (2016 - 2026)

Spyre Therapeutics' Interest & Investment Income history spans 11 years, with the latest figure at $7.1 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 23.6% year-over-year to $7.1 million; the TTM value through Dec 2025 reached $24.9 million, up 16.77%, while the annual FY2025 figure was $24.9 million, 16.77% up from the prior year.
  • Interest & Investment Income reached $7.1 million in Q4 2025 per SYRE's latest filing, up from $5.4 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $7.1 million in Q4 2025 to a low of $19000.0 in Q2 2021.
  • Average Interest & Investment Income over 5 years is $2.7 million, with a median of $835500.0 recorded in 2023.
  • Peak YoY movement for Interest & Investment Income: tumbled 92.67% in 2021, then soared 1591.43% in 2024.
  • A 5-year view of Interest & Investment Income shows it stood at $34000.0 in 2021, then surged by 1105.88% to $410000.0 in 2022, then skyrocketed by 906.34% to $4.1 million in 2023, then soared by 39.99% to $5.8 million in 2024, then increased by 23.6% to $7.1 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Interest & Investment Income are $7.1 million (Q4 2025), $5.4 million (Q3 2025), and $5.9 million (Q2 2025).